Marco Investment Management LLC Has $22.48 Million Holdings in Stryker Corporation $SYK

Marco Investment Management LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,830 shares of the medical technology company’s stock after acquiring an additional 1,230 shares during the period. Stryker makes up approximately 1.9% of Marco Investment Management LLC’s investment portfolio, making the stock its 16th largest holding. Marco Investment Management LLC’s holdings in Stryker were worth $22,484,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Brighton Jones LLC increased its stake in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Stryker by 2.2% during the first quarter. Brown Advisory Inc. now owns 47,079 shares of the medical technology company’s stock worth $17,525,000 after acquiring an additional 993 shares in the last quarter. Axxcess Wealth Management LLC raised its holdings in shares of Stryker by 3.9% during the first quarter. Axxcess Wealth Management LLC now owns 5,223 shares of the medical technology company’s stock worth $1,944,000 after acquiring an additional 196 shares during the period. Cerity Partners LLC lifted its position in Stryker by 17.4% in the 1st quarter. Cerity Partners LLC now owns 271,069 shares of the medical technology company’s stock valued at $100,912,000 after acquiring an additional 40,140 shares in the last quarter. Finally, Mar Vista Investment Partners LLC lifted its position in Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after acquiring an additional 8,353 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 520,500 shares of company stock valued at $184,803,065 in the last quarter. 5.90% of the stock is currently owned by corporate insiders.

Stryker Price Performance

NYSE:SYK opened at $355.74 on Friday. The stock has a market capitalization of $136.04 billion, a PE ratio of 47.12, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The firm has a fifty day simple moving average of $374.63 and a 200 day simple moving average of $380.99. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the company posted $2.87 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SYK. Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Truist Financial restated a “hold” rating and issued a $392.00 target price (down previously from $407.00) on shares of Stryker in a research note on Monday, November 3rd. Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Barclays boosted their price objective on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $433.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.